[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339821-105":59,"doc-detail-339821-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-novel-regulated-cell-death-ferroptosis-pyroptosisand-necroptosis-in-anti-pd-1pd-l1-cancer-immunotherapy","Targeting novel regulated cell death - Ferroptosis, pyroptosisand necroptosis in anti-PD-1/PD-L1 cancer immunotherapy","","Chemotherapy, radiotherapy, and immunotherapy provide core strategies for tumour treatment, yet immune checkpoint inhibitors show limited effectiveness because many cancers respond poorly. Anti-PD-1/PD-L1 therapies activate CD8+ T cells, enabling non-apoptotic regulated cell death programs such as ferroptosis, pyroptosis, and necroptosis. This review summarizes emerging roles and mechanisms of these regulated cell death forms in anti-PD-1/PD-L1 immunotherapy, highlighting synergy between nanomaterials and PD-1/PD-L1 inhibitors to improve antitumor efficacy across cancer types. It also frames cell-death signalling pathway targeting as a promising combination immunotherapy approach.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-novel-regulated-cell-death-ferroptosis-pyroptosisand-necroptosis-in-anti-pd-1pd-l1-cancer-immunotherapy/339821/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-novel-regulated-cell-death-ferroptosis-pyroptosisand-necroptosis-in-anti-pd-1pd-l1-cancer-immunotherapy/339821.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are anti-PD-1/PD-L1 immune checkpoint inhibitors not effective for all patients?","Question",{"text":112,"@type":113},"Only a subset of patients benefits from immune checkpoint blockade. The limitation is associated with poor responses and the contribution of alternative PD-1/PD-L1-related pathways to immunopathogenesis and treatment resistance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What non-apoptotic regulated cell death forms are discussed in anti-PD-1/PD-L1 therapy?",{"text":117,"@type":113},"The review focuses on ferroptosis, pyroptosis, and necroptosis as novel non-apoptotic regulated cell death programs that can be initiated in connection with anti-PD-1/PD-L1 immunotherapy.",{"name":119,"@type":110,"acceptedAnswer":120},"How can combining RCD inducers with immune checkpoint inhibition enhance antitumor effects?",{"text":121,"@type":113},"RCD induction can trigger non-apoptotic cell death in cancer cells, and combining such inducers with anti-PD-1/PD-L1 treatment is described as enhancing antitumor efficacy. The synergy is further emphasized between nanomaterials and PD-1/PD-L1 inhibitors across different cancer types.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339821,1790406660,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","DOI: 10.1111/cpr.13644  \nREVIE W  \nTargeting novel regulated cell death: Ferroptosis, pyroptosisand necroptosis in anti-PD-1/PD-L1 cancer immunotherapy  \nLi Yu 1,2  | Ke Huang 1 | Yixiang Liao 2 | Lingzhi Wang 3,4,5 | Gautam Sethi 3,5  | Zhaowu Ma 1   \n1Health Science Center, Yangtze University, Jingzhou, Hubei, China  \n2Department of Urology, Jingzhou Central Hospital, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, Hubei, China 3Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore  \n4Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore  \n5NUS Centre for Cancer Research (N2CR), National University of Singapore, Singapore, Singapore  \nCorrespondence  \nZhaowu Ma, Health Science Center, Yangtze University, Nanhuan Road 1, Jingzhou, Hubei 434023, China. [Email:](Email: mazw@yangtzeu.edu.cn)[ mazw@yangtzeu.edu.cn](Email: mazw@yangtzeu.edu.cn)  \nGautam Sethi, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 117600, Singapore. Email: [phcgs@nus.edu.sg](phcgs@nus.edu.sg)  \nLingzhi Wang, Cancer Science Institute of Singapore, National University of Singapore, 117600, Singapore.  \nEmail: [csiwl@nus.edu.sg](csiwl@nus.edu.sg)  \nFunding information  \nBelt and Road Initiative Innovative Talent Exchange Foreign Expert Project, Grant/Award Number: DL2023027001L; Singapore Ministry of Health's National Medical Research Council, Grant/Award Number: NMRC/ CNIG/1146/2016; Joint NCIS and NUS Cancer Pro-gram Seed Funding Grants, Grant/Award Number: 2020/R713-009-272-733  \nAbstract  \nChemotherapy, radiotherapy, and immunotherapy represent key tumour treatment strategies. Notably, immune checkpoint inhibitors (ICIs), particularly anti-programmed cell death 1 (PD1) and anti-programmed cell death ligand 1 (PD-L1), have shown clinical efficacy in clinical tumour immunotherapy. However, the limited effectiveness of ICIs is evident due to many cancers exhibiting poor responses to this treatment. An emerging avenue involves triggering non-apoptotic regulated cell death (RCD), a significant mechanism driving cancer cell death in diverse cancer treatments. Recent research demonstrates that combining RCD inducers with ICIs significantly enhances their antitumor efficacy across various cancer types. The use of anti-PD-1/PD-L1 immunotherapy activates CD8+ T cells, prompting the initiation of novel RCD forms, such as ferroptosis, pyroptosis, and necroptosis. However, the functions and mechanisms of non-apoptotic RCD in anti-PD1/PD-L1 therapy remain insufficiently explored. This review summarises the emerging roles of ferroptosis, pyroptosis, and necroptosis in anti-PD1/PD-L1 immunotherapy. It emphasises the synergy between nanomaterials and PD-1/PD-L1 inhibitors to induce non-apoptotic RCD in different cancer types. Furthermore, targeting cell death signalling pathways in combination with anti-PD1/PD-L1 therapies holds promise as a prospective immunotherapy strategy for tumour treatment.  \n\n| Li Yu and Ke Huang contributed equally to this work and should be considered co-first authors. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2024 The Authors. Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd. |\n\nCell Prolif. 2024;57:e13644 .  \n[https://doi.org/10.1111/cpr.13644](https://doi.org/10.1111/cpr.13644)  \n[onlinelibrary.wiley.com/journal/13652184](onlinelibrary.wiley.com/journal/13652184)  \n1 of 16  \n1 | INTRODUCTION  \nThe application of immune checkpoint inhibitors (ICIs) in cancer immunotherapy has shown remarkable success in clinical settings. 1,2 Since their initial FDA approval in 2011, ICIs have rapidly become integral to various cancer treatment protocols.3 Th","cbCaijwWb4ofAN41","https://ap.wps.com/l/cbCaijwWb4ofAN41","pdf",2262863,16,"English","# Introduction\n## Immune checkpoint inhibitors in cancer immunotherapy\n## Regulated cell death and major subroutines\n## Links to tumour microenvironment modulation","[{\"question\":\"Why are anti-PD-1/PD-L1 immune checkpoint inhibitors not effective for all patients?\",\"answer\":\"Only a subset of patients benefits from immune checkpoint blockade. The limitation is associated with poor responses and the contribution of alternative PD-1/PD-L1-related pathways to immunopathogenesis and treatment resistance.\"},{\"question\":\"What non-apoptotic regulated cell death forms are discussed in anti-PD-1/PD-L1 therapy?\",\"answer\":\"The review focuses on ferroptosis, pyroptosis, and necroptosis as novel non-apoptotic regulated cell death programs that can be initiated in connection with anti-PD-1/PD-L1 immunotherapy.\"},{\"question\":\"How can combining RCD inducers with immune checkpoint inhibition enhance antitumor effects?\",\"answer\":\"RCD induction can trigger non-apoptotic cell death in cancer cells, and combining such inducers with anti-PD-1/PD-L1 treatment is described as enhancing antitumor efficacy. The synergy is further emphasized between nanomaterials and PD-1/PD-L1 inhibitors across different cancer types.\"}]","Targeting novel regulated cell death - Ferroptosis, pyroptosisand necroptosis in anti-PD-1/PD-L1 cancer immunotherapy | PDF",1790032442,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e00df08dec2dd678177ef48d164a6dc0.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/167507d276ccc0a08bd0d48ac4a11926.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a179990faf149a581c00f9a3fd3d029c.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0849845a25c37d5464e138b1bb134a98.webp",980,1287]